Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 7/20 | 0.61 |
| ▸ | CA1 | P00915 | 5/20 | 0.61 |
| ▸ | CA9 | Q16790 | 5/20 | 0.61 |
| ▸ | CA6 | P23280 | 3/20 | 0.61 |
| ▸ | CA12 | O43570 | 3/20 | 0.61 |
| ▸ | CA4 | P22748 | 2/20 | 0.61 |
| ▸ | CA5A | P35218 | 2/20 | 0.61 |
| ▸ | CA7 | P43166 | 2/20 | 0.61 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.61 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.61 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.61 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | CDK2 | P24941 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | TTR | P02766 | 1/20 | 0.42 |
| ▸ | HTR6 | P50406 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10808580 | 0.86 | CA2 (0.52) | CA2CA1CA9CA6CA12 | |
| SCHEMBL8180224 | 0.84 | GAA (0.60) | CA2CA1CA9CA6CA12 | |
| SCHEMBL11477215 | 0.83 | CYP3A4 (0.54) | CA2CA1CA9CA6CA12 | |
| SCHEMBL7484553 | 0.81 | CYP3A4 (0.52) | CA2CA1CA9CA6CA12 | |
| SCHEMBL2184171 | 0.81 | TTR (0.60) | CA2CA1CA9CA6CA12 | |
| SCHEMBL401308 | 0.80 | CA2 (0.47) | CA2CA1CA9CA6CA12 | |
| SCHEMBL31310995 | 0.80 | CA2 (0.47) | CA2CA1CA9CA6CA12 | |
| SCHEMBL8480118 | 0.78 | CA2 (0.61) | CA2CA1CA9CA6CA12 | |
| Hydrochloric Acid SCHEMBL1017217 | 0.78 | CA2 (0.45) | CA2CA1CA9CA6CA12 | |
| SCHEMBL31370840 | 0.78 | CA2 (0.61) | CA2CA1CA9CA6CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109422748-A | The method for synthesizing TNNI3K inhibitor | 南京理工大学 | 2019-03-05 | — | — | CN | claimed |
| EP-1451160-B1 | PYRAZOLE-AMIDES FOR USE IN THE TREATMENT OF PAIN | ICAGEN INC (US) | 2010-01-13 | — | — | EP | claimed |
| EP-1490044-A4 | COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS | NEUROGEN CORP (US) | 2008-04-16 | — | — | EP | claimed |
| EP-1490044-A1 | COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS | NEUROGEN CORPORATION (US) | 2004-12-29 | — | — | EP | claimed |
| WO-2003084524-A1 | COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS | NEUROGEN CORPORATION (US) | 2003-10-16 | — | — | WO | claimed |
| CN-109422748-A | The method for synthesizing TNNI3K inhibitor | 南京理工大学 | 2019-03-05 | — | — | CN | disclosed |
| CN-104829542-B | Aniline pyrimidine class compound, its preparation method and medical usage | 中国科学院上海药物研究所 | 2018-02-02 | — | — | CN | disclosed |
| EP-2646431-A1 | A PROCESS FOR THE PREPARATION OF PAZOPANIB USING NOVEL INTERMEDIATE | Hetero Research Foundation (IN) | 2013-10-09 | — | — | EP | disclosed |
| WO-2012073254-A1 | A PROCESS FOR THE PREPARATION OF PAZOPANIB USING NOVEL INTERMEDIATE | HETERO RESEARCH FOUNDATION (IN) | 2012-06-07 | — | — | WO | disclosed |
| EP-1451160-B1 | PYRAZOLE-AMIDES FOR USE IN THE TREATMENT OF PAIN | ICAGEN INC (US) | 2010-01-13 | — | — | EP | disclosed |
| US-20080064690-A1 | PYRAZOLE-AMIDES AND -SULFONAMIDES | ICAGEN, INC. (US) | 2008-03-13 | — | — | US | disclosed |
| WO-2007148116-A2 | TOPICAL PHARMACEUTICAL FORMULATIONS | ASTON UNIVERSITY (GB) | 2007-12-27 | — | — | WO | disclosed |
| US-7223782-B2 | Pyrazole-amides and -sulfonamides | ICAGEN, INC. (US) | 2007-05-29 | — | — | US | disclosed |
| US-20050049237-A1 | Pyrazole-amides and -sulfonamides | ICAGEN, INC. (US) | 2005-03-03 | — | — | US | disclosed |
| CN-1145031-A | Starch-metal complexes for skin and hair | SKIN BIOLOGY INC (US) | 1997-03-12 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080064690-A1 | PYRAZOLE-AMIDES AND -SULFONAMIDES | SCN3A, TRPV3, HCN3 | CA2 315/4885CA1 1399/4885CA9 2865/4885 |
| US-20050049237-A1 | Pyrazole-amides and -sulfonamides | SCN3A, TRPV3, HCN3 | CA2 315/4885CA1 1399/4885CA9 2865/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.